Gene and protein expression profiles associated with the therapeutic efficacy of EGFR-TK inhibitors
US8088589B2 · kind B2 · utility
1Cited by
1References
1Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 8, 2009 |
| Grant date | Jan 3, 2012 |
| Priority date | — |
| Expiry date | Jun 12, 2029 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/71
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention provides protein and gene expression profiles indicative of whether a patient afflicted with non-small cell lung cancer is likely to be responsive to treatment with a therapeutic compound that is a EGFR-TK inhibitor. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and protein expression profiles, and assays for identifying the presence of a gene or protein expression profile in a patient sample.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.